Status:

COMPLETED

Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients

Lead Sponsor:

Institut du Cancer de Montpellier - Val d'Aurelle

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to compare normalization of vitamin D serum level after 6 months of vitamin D supplementation adjusted to baseline vitamin D serum level vs.conventional vitamin D suppleme...

Eligibility Criteria

Inclusion

  • Breast adenocarcinoma treated by neoadjuvant or adjuvant chemotherapy within 12 months prior to study enrollment
  • WHO performance status 0-1
  • Age ≥18 years old
  • Affiliation to a social security regime or beneficiary of equivalent social protection
  • Written informed consent provided before any study specific procedures
  • Complementary inclusion criterion for randomization
  • \- Proved vitamin D deficiency as defined by serum vitamin D level lower than 30 ng/ml (75 nmol/L).

Exclusion

  • Metastatic disease
  • History or presence of any other malignancy (except curatively treated nonmelanoma skin cancer or in situ cervix carcinoma) ………….
  • traités dans les 5 ans précédents.
  • Contraindication to calcium or cholecalciferol
  • Known severe hypersensitivity to vitamin D or to calcium supplementation or to one of the excipients.
  • Disease and/or medical conditions accompanied by hypercalcaemia and/or hypercalciuria
  • Calcium lithiasis and tissue calcification
  • Hypervitaminosis D
  • Presence of significant comorbidities:
  • i) Uncontrolled endocrine disease ii) Known disorders of calcium phophorus laboratory testing iii) Proved osteopenia or osteoporosis requiring vitamin D and calcium supplements
  • Concomitant treatment with other experimental products or another vitamin D calcium treatment
  • Pregnancy, breastfeeding or of reproductive potential not using an effective contraceptive method
  • Legal inability or restricted legal ability. Medical or psychological conditions not allowing proper study completion or informed consent signature

Key Trial Info

Start Date :

July 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2014

Estimated Enrollment :

215 Patients enrolled

Trial Details

Trial ID

NCT01480869

Start Date

July 1 2011

End Date

December 1 2014

Last Update

September 10 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CRLC Val d'Aurelle-Paul Lamarque

Montpellier, France, 34298